Sleep Disorders Trial, Recruiting NCT06532773 Sponsor: Duke University Condition: Sleep Disorders
Back to Sleep Disorders

Sleep Disorders Trial, Recruiting

NCT06532773
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults aged 18 or older, of any gender
  • People who have been recently diagnosed or re-diagnosed with acute myeloid leukemia, acute lymphoblastic leukemia, Non-Hodgkin's lymphoma, multiple myeloma, or myelodysplastic syndrome
  • People who are staying in hospital for at least 7 days to receive treatment, such as chemotherapy or CAR-T immunotherapy
  • People who are experiencing sleep difficulties, scoring 8 or higher on a standard sleep problem questionnaire measuring the past 7 days
  • People who can speak and read English, and who have adequate hearing and vision

Who may not be able to join:

  • People who have, or are suspected to have, significant difficulties with memory or thinking, as measured by a standard cognitive assessment (a score below 25 on the Folstein Mini-Mental Status Exam)
  • People with a serious psychiatric condition (such as schizophrenia or active thoughts of suicide) or certain serious medical conditions (such as a seizure disorder or narcolepsy), as identified through medical records or by a treating doctor or other healthcare provider
  • People whose treating medical team expects them to survive less than 6 months

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 16 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 919-416-3471

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Registry
ClinicalTrials.gov
Start date
14 January 2026
Est. completion
30 June 2029

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Feasibility as measured by study accrual; Feasibility as measured by study attrition; Feasibility as measured by adherence; Acceptability as measured by the Client Satisfaction Questionnaire (CSQ); Engagement as measured by Nite2Day+ app and skills use; Change in insomnia symptoms

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov